Trials / Completed

CompletedNCT00670267

Oral Nadolol for the Treatment of Adults With Mild Asthma

An Open-Label, Dose-Escalating, Study to Evaluate the Safety, Efficacy and Tolerability of Oral Nadolol for the Treatment of Adults With Mild Asthma

Status: Completed
Phase: Phase 1 / Phase 2
Study type: Interventional
Enrollment: 10 (actual)

Sponsor: Invion, Inc. · Industry
Sex: All
Age: 18 Years – 60 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.

Conditions

Asthma

Interventions

Type	Name	Description
DRUG	nadolol	Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.

Timeline

Start date: 2007-01-01
Primary completion: 2009-05-01
Completion: 2009-06-01
First posted: 2008-05-01
Last updated: 2016-05-11
Results posted: 2016-05-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00670267. Inclusion in this directory is not an endorsement.